Hydralazine hoarseness. A new appearance of drug-induced systemic lupus erythematosus.
Otolaryngologic involvement is rarely a manifestation of drug-induced systemic lupus erythematosus (SLE). Hoarseness developed in a 60-year-old man that was secondary to ulcerated lesions, which involved the epiglottis and aryteno-epiglottic folds, with serologic evidence of SLE after he had been treated with hydralazine for six months. Histopathologic study of an epiglottic "pseudotumor" disclosed necrotizing vasculitis. To our knowledge, this is the first reported case of laryngeal involvement as a complication of hydralazine-induced SLE.
D004825:Epiglottis / Q000473:pathology; D006685:Hoarseness / Q000139:chemically induced*; D006801:Humans; D006830:Hydralazine / Q000009:adverse effects*; D007818:Laryngeal Diseases / Q000139:chemically induced; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D014456:Ulcer / Q000139:chemically induced; D014657:Vasculitis / Q000139:chemically induced
D006830:Hydralazine